Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... , Cytoflavin with CER175003 RUB has the advantage.It was determined that the preferred scheme of treatment ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... and macrolides, most commonly used in the treatment of acute obstructive bronchitis. Materials and methods. data ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... Abstract: the acute disturbances of cerebral circulation incidence accounts for nearly 70-80 ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... -effectiveness ratio (CER) and budget impact analysis (BIA) were performed. All calculations were made in the MS ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... /лерканидипин и зофеноприл/лерканидипин. Проведен ABC/VEN-анализ, анализ «затраты-эффективность», сравнительная ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... /лерканидипин и зофеноприл/лерканидипин. Проведен ABC/VEN-анализ, анализ «затраты-эффективность», сравнительная ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... group was 0,358 and 0,134 in the second group. The cost-utility ratio for first group was 39 090,5 RUB ..."
 
Vol 9, No 4 (2016) ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ КОМБИНАЦИИ ОЛМЕСАРТАН/ЛЕРКАНИДИПИН И ЗОФЕНОПРИЛ/ЛЕРКАНИДИПИН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ Abstract  similar documents
"... /Лерканидипин. Проведен  ABC/VEN-анализ, анализ « Затраты - эффективность», сравнительная оценка частоты ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... обеспечения Microsoft Excel разработаны две модели для проведения анализа минимизации затрат (модель 1) и ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS Abstract  similar documents
M. V. Protsenko
"... «минимизация затрат», анализа «затраты – полезность», анализа «порога «готовности платить» и анализа «влияния ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... of registration in the case of inclusion in the Essential Drugs List (0,5% R-R amp. 10 ml №10 – 947,74 RUB; 0 ..."
 
Vol 9, No 3 (2016) МЕТОД «ЗАТРАТЫ – ЭФФЕКТИВНОСТЬ» В ОЦЕНКЕ АНТИБИОТИКОТЕРАПИИ ОСТРОГО ОБСТРУКТИВНОГО БРОНХИТА У ДЕТЕЙ В УСЛОВИЯХ СТАЦИОНАРА Abstract  similar documents
,
"... сопоставления затрат и эффективности сравниваемых курсов  терапии острого обструктивного бронхита был применен ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... фармакоэкономический анализ «затраты-полезность» (cost-utilityanalysis CUA) является третьим по ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... as the effectiveness criterion. The CER amounted to 440,759 roubles for Reamberin, 543,991 roubles for the Ringer ..."
 
Vol 7, No 1 (2014) ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN Abstract  similar documents
V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva
"... фармакоэкономическими преимуществами, способствуя снижению затрат на достижение контроля и стои- мость одного ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... in combination with metformin equal to 1 348368 rub, 1 161874 rub and 537331 rub for QALY in comparison ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... 198 300 RUB for 6DAC and 1 371 184 RUB for 6FAC. Direct and indirect costs rate of the breast cancer ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... (CER) showed that the annual cost of effective treatment of DTC refractive to radioactive iodine ..."
 
Vol 9, No 2 (2016) PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION Abstract  similar documents
T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva
"... Целью исследования было проведение анализа структуры и рациональности затрат на обеспечение ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... , the adoption of perampanel is projected to increase drug costs (in millions) by RUB15.2 (1.2%), RUB76.1 (6 ..."
 
Vol 10, No 2 (2017) ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) Abstract  similar documents
Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina
"... practice (RUB 4913,67 and 17837,71 respectively). The present analysis demonstrates that the PAP ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... disappears, and the CA drugs have a lower CER instead. For the «number of  hospitalization-free days per year ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... was increased to 24 months, this economic advantage of AA diminished, and the kA drugs had a lower CeR instead ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... протяжении 19 лет применение нилотиниба является доминантным, с точки зрения анализа «затраты-полезность», и ..."
 
Vol 7, No 1 (2014) PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY Abstract  similar documents
D. V. Blinov
"... гипоксически-ишемического поражения ЦНС, что может быть примером прямого влияния на затраты для лечения и ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... миелолейкоз (ХМЛ) в хронической фазе (ХФ). Результаты анализа «затраты-эффективность», выполненного с ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... , где CER – показатель «затраты – эффективность»; Cost – затраты на медицинскую технологию, руб.; Ef ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... Федерации.  Результаты: Коэффициенты «затраты-эффективность» при использовании Ревлимида во второй линии ..."
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... – to 159 153 118 rub, thus the saved means allow to treat with this strategy in addition 29 patients during ..."
 
Vol 7, No 1 (2014) ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT Abstract  similar documents
M. A. Shapovalova, L. R. Koretskaya
"... учреждении � АВС и VEN анализы затрат на лекарственные средства и медицинских затрат на лечение пациента ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... . Results. In patients with relapsed or refractory CD30-positive HL after ASCT ICER was 5,8 million rub. per ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... изменение биохимических параметров (HbA1c, липидограммы, артериального давления). Проведен анализ «затраты ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... был использован коэффициент «затраты-эффективность». Результаты. Проведенный анализ показал, что ..."
 
Vol 11, No 3 (2018) Use of medications in children hospitalized with community-acquired pneumonia Abstract  similar documents
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova
"... with that, 45.70% of  patients had concomitant diseases; among those, acute respiratory infections of the upper ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... assignment of the second line drugs. Reducing their use and rational therapy of acute conditions will enable ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... posttransplantation period. Results. Everolimus plus reduced-exposure cyclosporine leads to cost reduction by 161 RUB ..."
 
Vol 12, No 1 (2019) Individual cost accounting in the management of medical organizations Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali
"... планирование расходов и комплексная оптимизация процессов. Изучение затрат позволяет выработать правильную ..."
 
Vol 5, No 1 (2012) PHARMACOECONOMIC EVALUATION OF THE PROPHYLAXIS OF POSTSURGICAL INFECTIOUS INFLAMMATORY COMPLICATIONS OF COMBINED ANTIBIOTIC DRUGS AND CORTICOSTEROIDS IN OPHTHALMIC PRACTICE IN RUSSIAN FEDERATION Abstract  similar documents
V. G. Serpik, R. I. Yagudina
"... Комбинил-Дуо по коэффициенту «затраты-эффективность», в качестве которого была использована стоимость ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpik
"... анализа «затраты-эффективность». Результаты показали, что препарат Азопт обладает преимуществом над ..."
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... that of eribulin, and even at mid-optimal doses (1.5 mg/m2 ) exceeded 2xWPT. The cost estimating relationship (CER ..."
 
Vol 11, No 1 (2018) CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation Abstract  similar documents
A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
"... remains cost-effective even if the genotyping costs more than 3893.8 RUB  (199% of the current value ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS Abstract  similar documents
O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina
"... «минимизации затрат» положено фактическое количество пациентов (57 человек) с РЗ, которым ранее была ..."
 
Vol 5, No 2 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpikov
"... использованием методов анализа «влияния на бюджет» и анализа «затраты эффективность» получены следующие ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... в статье представлены результаты расчета необходимых финансовых затрат на лекарственное ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... В статье проводится обзор международного опыта использования механизма разделения затрат в целях ..."
 
Vol 9, No 2 (2016) EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL Abstract  similar documents
I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova
"... Цель — изучить рациональность финансовых затрат на лечение пациентов с тяжелым течением пневмонии ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
 
1 - 50 of 169 Items 1 2 3 4 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)